Evidence map›Paper›PMID 39421451›Full record

ArticleFrontiers in oncology2024

A study of pre- and post-treatment hematologic markers of immune response in patients undergoing radiotherapy for soft tissue sarcoma.

Eric Ku, Garrett Harada, Grace Lee, Akul Munjal, Nicholas Peterson, Jino Park, Warren Chow, Russell Stitzlein, Charles Limoli, Jeremy Harris

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eric KuDepartment of Radiation Oncology, University of California Irvine, Orange, CA, United States.
Garrett HaradaDepartment of Radiation Oncology, University of California Irvine, Orange, CA, United States.
Grace LeeSchool of Medicine, University of California Irvine, Irvine, CA, United States.
Akul MunjalDepartment of Radiation Oncology, University of California Irvine, Orange, CA, United States.
Nicholas PetersonDepartment of Radiation Oncology, University of California Irvine, Orange, CA, United States.
Jino ParkDepartment of Radiation Oncology, University of California Irvine, Orange, CA, United States.
Warren ChowDepartment of Hematology/Oncology, University of California Irvine, Orange, CA, United States.
Russell StitzleinDepartment of Orthopedic Surgery, University of California Irvine, Orange, CA, United States.
Charles LimoliDepartment of Radiation Oncology, University of California Irvine, Orange, CA, United States.
Jeremy HarrisDepartment of Radiation Oncology, University of California Irvine, Orange, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study investigates the impact of pre- and post-treatment hematologic markers, specifically neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), on treatment outcomes in soft tissue sarcoma (STS) patients undergoing radiation therapy (RT). Methods: Data from 64 patients who underwent RT for curative management of STS were reviewed. Pre-RT and post-RT hematologic measures were evaluated for associations with survival outcomes. A normal tissue complication probability (NTCP) curve for predicting ΔPLR ≥ 75 was modeled using a probit function. Results: Elevated baseline NLR was associated with worse overall survival (OS) and disease-free survival (DFS), while elevated PLR was associated with worse DFS. Post-RT, elevated PLR was linked to worse OS and DFS. Increasing PLR change post-RT was associated with worse OS and DFS. Receiver operating characteristics analysis determined ΔPLR ≥ 75 to be a robust cutoff associated with worse DFS. Bone V10Gy ≥362 cc corresponded to a 50% risk of developing ΔPLR ≥ 75. Discussion: These results suggest that hematologic markers could serve as prognostic biomarkers in both pre- and post-treatment settings for STS patients undergoing RT. Future studies can consider using bone V10Gy < 362 cc as a potential cutoff to reduce the risk of increased PLR after RT.

Indexed as

dosimetryNLRPLRradiationsarcoma

Identifiers

PMID39421451
PMCPMC11484061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.